4 ms·

> would the data from my wearable have helped healthcare professionals with my treatment? This presumes doctors practicing medicine 2.0 have any effective trea

> would the data from my wearable have helped healthcare professionals with my treatment? This presumes doctors practicing medicine 2.0 have any effective treatment. For the flu, sure there is tamiflu; or COVID, paxlovid; but absent those 2, for the short term interference; the best options are somewhere between zinc lazenges, creatine, water, and sleep. Both the flu and COVID now have vaccines, which are more effective and preventative than interfering treatments. Anti-biotics should, generally, rarely be given at early stage, unless there are significant factors, as they have both individual and population level side effects. Now, can a glucose monitor or testing cortisol or liver proteins more often tell you something? Yes, but not with much more actionable items than eat healthy, work out, sleep more, drink less (Yes, there is hrt, glp1s - but those are unlikely to be prescribed if the issue is not significant over a longer term)

thedrbrian 2y ago
>This presumes doctors practicing medicine 2.0 have any effective treatment. For the flu, sure there is tamiflu; or COVID, paxlovid; don't know if you were being intentionally sarcastic when naming those two as effective treatments >How effective is Tamiflu? Unfortunately, the effectiveness of Tamiflu is marginal, as it cannot “cure” the illness. Most studies have shown that the medication will reduce the length of symptoms by only 12 to 24 hours, and if started after two days of symptoms, it does not help at all. It is important to keep effectiveness in mind, as expectations for Tamiflu are often very high and, frankly, overhyped. https://health.mountsinai.org/blog/is-it-worth-it-to-take-tamiflu/ https://health.mountsinai.org/blog/is-it-worth-it-to-take-ta... >Paxlovid does not significantly alleviate symptoms of COVID-19 compared with placebo among nonhospitalized adults, a new study published on April 3 in The New England Journal of Medicine found. The results suggest that the drug, a combination of nirmatrelvir and ritonavir, may not be particularly helpful for patients who are not at high risk for severe COVID-19. https://www.medscape.com/viewarticle/study-shows-nirmatrelvir-ritonavir-no-more-effective-than-2024a10006gb https://www.medscape.com/viewarticle/study-shows-nirmatrelvi... which links to https://www.nejm.org/doi/full/10.1056/NEJMoa2309003 https://www.nejm.org/doi/full/10.1056/NEJMoa2309003 and this little nugget >CONCLUSIONS The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo.

thedrbrian 2y ago

>This presumes doctors practicing medicine 2.0 have any effective treatment. For the flu, sure there is tamiflu; or COVID, paxlovid; don't know if you were being intentionally sarcastic when naming those two as effective treatments >How effective is Tamiflu? Unfortunately, the effectiveness of Tamiflu is marginal, as it cannot “cure” the illness. Most studies have shown that the medication will reduce the length of symptoms by only 12 to 24 hours, and if started after two days of symptoms, it does not help at all. It is important to keep effectiveness in mind, as expectations for Tamiflu are often very high and, frankly, overhyped. https://health.mountsinai.org/blog/is-it-worth-it-to-take-tamiflu/ https://health.mountsinai.org/blog/is-it-worth-it-to-take-ta... >Paxlovid does not significantly alleviate symptoms of COVID-19 compared with placebo among nonhospitalized adults, a new study published on April 3 in The New England Journal of Medicine found. The results suggest that the drug, a combination of nirmatrelvir and ritonavir, may not be particularly helpful for patients who are not at high risk for severe COVID-19. https://www.medscape.com/viewarticle/study-shows-nirmatrelvir-ritonavir-no-more-effective-than-2024a10006gb https://www.medscape.com/viewarticle/study-shows-nirmatrelvi... which links to https://www.nejm.org/doi/full/10.1056/NEJMoa2309003 https://www.nejm.org/doi/full/10.1056/NEJMoa2309003 and this little nugget >CONCLUSIONS The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo.